• Biome's probiotic strain BMB18 demonstrated ability to modulate immune responses, reduce oxidative stress, and maintain intestinal barrier integrity
• Results will inform future clinical research opportunities and potential health applications for this strain
• Positive findings on BMB18's functional characteristics provide significant potential for new product development and broadening existing products

Biome Australia Limited (ASX: BIO) has received positive results from core functional characterization studies conducted on its probiotic strain BMB18. The in vitro studies, carried out by one of Biome's key research partners, investigated several functional characteristics of BMB18 using Caco-2 cell assays and peripheral blood mononuclear cells (PBMCs). The findings showcase the probiotic strain's functional potential, demonstrating its ability to effectively modulate immune responses and inflammation, reduce oxidative stress, and maintain intestinal barrier integrity. The researchers indicated that the strain's ability to reduce inflammation and enhance immune responses may provide benefits in conditions with immune dysregulation, such as chronic intestinal diseases or food intolerances. The modulation of oxidative stress demonstrated by BMB18 was also suggested to be a critical factor in conditions like cardiovascular diseases, neurodegenerative disorders, and other chronic inflammatory diseases. Additionally, the study found that BMB18 enhances epithelial barrier integrity and reduces permeability, indicating its potential to counter dysfunctions seen in various intestinal disorders. Biome's Managing Director and Founder, Blair Vega Norfolk, expressed his satisfaction with this significant development, stating that the new data provides critical insights into the functional characteristics and potential downstream applications for the novel strain. As Biome continues the development of BMB18 as a key component of its Vision 27, the positive results present a significant potential commercial pipeline for new product development and broadening the use of existing products.

As Biome continues the development of BMB18 as a key component of its Vision 27, the positive results present a significant potential commercial pipeline for new product development and broadening the use of existing products.